Hereditary Angioedema (HAE), Treatment and Prophylaxis

Coverage Summary

Overall coverage stance: Mixed. This is a medical benefit drug policy addressing C1 esterase inhibitors and a plasma kallikrein inhibitor for hereditary angioedema (HAE). Scope: medical benefit coverage, medical necessity criteria, and applicable codes for Berinert, Ruconest, Kalbitor, and Cinryze for treatment of acute attacks and prophylaxis as specified. Berinert, Ruconest, and Kalbitor are covered for acute HAE attacks when criteria are met. Cinryze coverage is plan-dependent: under Medical Necessity Plans Cinryze is not medically necessary for HAE treatment (published evidence does not show superiority to other C1-INH products), while under Non-Medical Necessity Plans Cinryze is covered for prophylaxis when used for prophylaxis and not combined with other prophylactic HAE products. Effective date: November 1, 2025.

Initial Therapy Criteria (Medically Necessary)

Medically Necessary: Berinert, Ruconest, Kalbitor for treatment of HAE (Initial therapy)

Covered when ALL of the following are met:

ALL of the following

ONE of
- ALL of the following
  - C1-INH antigenic level below the lower limit of normal
  - C1-INH functional level below the lower limit of normal
- OR
  - Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosamine 3-O-sulfotransferase 6
  - Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
Used for treatment of an acute HAE attack
Not used in combination with other approved treatments for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor or Ruconest)
Claims may be denied if drugs are used in combination
Prescriber specialty
- Prescribed by an Immunologist
- Prescribed by an Allergist
Product-specific requirements
- For Berinert requests only: submission of medical records documenting a history of failure, contraindication, or intolerance to Ruconest (C1 esterase inhibitor (recombinant))
- For Berinert and Ruconest requests only: physician attestation that the patient is unable to self-administer or there is no competent caregiver to administer the drug
Initial authorization will be for no more than 12 months

Prior Authorization

Initial authorization requirements

Initial authorization is limited to no more than 12 months. For Berinert requests, submission of medical records must document a history of failure, contraindication, or intolerance to Ruconest. For Berinert and Ruconest requests, the physician must attest that the patient is unable to self-administer or there is no competent caregiver to administer the drug.

Affected codes: J0596, J0597, J1290
Berinert-specific requirement: medical records documenting failure, contraindication, or intolerance to Ruconest
Berinert and Ruconest attestation: physician attestation that patient cannot self-administer or lacks competent caregiver
Initial authorization limited to no more than 12 months

Continuation Therapy Criteria (Reauthorization)

Medically Necessary: Continuation of therapy (Berinert, Ruconest, Kalbitor)

Covered when ALL of the following are met for continuation:

ALL of the following

Documentation of positive clinical response
Used for treatment of an acute HAE attack
Not used in combination with other approved treatments for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor or Ruconest)
Claims may be denied if drugs are used in combination
Prescriber specialty

Product-specific Coverage Notes

Coverage statement: Cinryze

Plan-dependent coverage:

ANY of the following

Medical Necessity Plans: Cinryze is NOT medically necessary for the treatment of hereditary angioedema (HAE) (published evidence does not demonstrate superiority to other C1 esterase inhibitors)
Non-Medical Necessity Plans: Cinryze is proven for prophylaxis against HAE attacks when BOTH of the following are met: used for prophylaxis against HAE attacks; and not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Haegarda, Takhzyro)

Documentation Required

Exclusions / Combination Therapy

Combination therapy exclusion: Use of therapies in combination for the treatment of an acute HAE attack is prohibited. Specifically, these products must not be used in combination with other approved treatments for acute HAE attacks (examples listed: Berinert, Firazyr, Kalbitor, or Ruconest). Claims may be denied if drugs are co-administered with other approved acute HAE treatments.

Denial Risk

Combination therapy exclusion

Claims may be denied if drugs are used in combination with other approved treatments for acute HAE attacks.

Affected codes: J0596, J0597, J1290, J0598
Claims may be denied if used in combination with other approved acute HAE treatments (e.g., Berinert, Firazyr, Kalbitor, Ruconest)

Applicable Codes

Applicable J-codes (reference list)HCPCS

J0596	Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units
J0597	Injection, C-1 esterase inhibitor (human), Berinert, 10 units
J0598	Injection, C1 esterase inhibitor (human), Cinryze, 10 units
J1290	Injection, ecallantide, 1 mg

Related diagnosis code (example provided)ICD-10

D84.1

Defects in the complement system

Provider Actions / Documentation & Billing

Documentation Required

Diagnosis confirmation

Document diagnostic confirmation of HAE by including laboratory or genetic results in the medical record. Acceptable documentation includes one of the following: abnormal C1-INH antigenic level below the laboratory lower limit of normal, abnormal C1-INH functional level below the laboratory lower limit of normal, a genetic variant consistent with HAE-unknown, or recurrent angioedema attacks refractory to high-dose antihistamines with a confirmed family history.

Document one of: abnormal C1-INH antigenic level OR abnormal C1-INH functional level
OR documented genetic variant consistent with HAE-unknown
OR recurrent attacks refractory to high-dose antihistamines with confirmed family history
Include lab results or genetic test results in the medical record

Documentation Required

Clinical Evidence

Supporting evidence: Key clinical trial findings summarized in this policy include phase 3 and pivotal trials demonstrating faster symptom relief or reduced attack rates with these agents. Examples: Ruconest phase 3 trial showed faster median time to symptom relief versus placebo (e.g., 75 vs 303 minutes by VAS; p=0.003); Berinert IMPACT trials demonstrated shorter median time to relief with C1-INH 20 U/kg versus placebo (0.5 vs 1.5 hours; p=0.0025) and consistent long-term response with 20 U/kg dosing; Kalbitor (ecallantide) EDEMA trials showed significant improvement in symptom scores at 4 hours versus placebo with benefit apparent within 2 hours and maintained to 24 hours; Cinryze prophylaxis studies showed a 93.7% reduction in attacks with twice-weekly dosing (1000 units twice weekly supported). Key references cited include randomized trials and guideline publications (e.g., Cicardi 2010; Riedl 2013; Zuraw 2012; Maurer 2018/2022; US HAEA 2020). Clinical evidence and references were refreshed per the Summary of Changes (policy updates reflected in the archive of prior version).

Background

Background and mechanism: C1-INH products (human plasma-derived: Berinert and Cinryze; recombinant: Ruconest) act by replacing or restoring C1 inhibitor activity and suppressing contact system activation to prevent generation of bradykinin, the principal mediator of HAE-related vascular permeability. Ruconest (recombinant) irreversibly binds and inactivates proteases such as kallikrein and factor XIIa, preventing bradykinin formation. Kalbitor (ecallantide) is a selective, reversible plasma kallikrein inhibitor that blocks conversion of high molecular weight kininogen to bradykinin, reducing bradykinin-mediated swelling during acute attacks. Product descriptions: Berinert and Cinryze are highly purified human plasma C1-INH preparations; Ruconest is a recombinant serine protease inhibitor; Kalbitor is a subcutaneous kallikrein inhibitor (ecallantide). Clinical trials: Ruconest randomized phase 3 trial and open-label studies demonstrated faster symptom relief versus placebo and sustained efficacy with repeated doses; Berinert IMPACT-1/2 trials and extension studies showed shorter time to symptom relief with 20 U/kg dosing and consistent long-term response without development of inhibitory antibodies; Kalbitor EDEMA trials demonstrated rapid and sustained reduction in symptom severity versus placebo; Cinryze prophylaxis trials showed marked reductions in attack frequency with twice-weekly 1000-unit dosing and favorable tolerability.

Definitions: HAE-unknown — Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (no family history).

Revision History

2025-11-01policy_changeLatest

Material: Removed from the pharmacy benefit list the self‑administered injections Firazyr (icatibant), Haegarda (C1 esterase inhibitor [human]), and Takhzyro (lanadelumab).

2025-11-01administrative_update

Clinical evidence and references refreshed; previous policy version 2024D0044O archived.